Amyloid fibril inhibition, acceleration, or fragmentation; Are nano-based approaches advance in the right direction?. (December 2020)

• Record Type: Journal Article
• Authors: Hajipour, Mohammad Javad; Mohammad-Beigi, Hossein; Nabipour, Iraj; Mahmoudi, Negar; Azhdarzadeh, Morteza; Derakhshankhah, Hossein; Dawud, Dina El; Mohammadinejad, Reza; Otzen, Daniel E.
• Is Part Of: Nano today. Volume 35(2020)
• Publication Date: 2020-12
• Subjects: Alzheimer's disease -- Fibrillation -- Aβ -- Nanotechnology -- Nanoparticles; Nanotechnology -- Periodicals; Nanosciences -- Périodiques; 620.505
• DOI: 10.1016/j.nantod.2020.100983
• Languages: English
• ISSNs: 1748-0132

Abstract

Graphical abstract: Highlights: The nanotechnology-based approaches have not been effective for AD therapy. The question is raised whether the nanotechnology-based strategies advance in right direction? Scientists should choose right targets and therapeutic strategies. Abstract: Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.